Voices
Early Discontinuation of ICIs in Patients Without Progression Did Not Compromise PFS or OS – ESMO Open
ESMO/LinkedIn

Early Discontinuation of ICIs in Patients Without Progression Did Not Compromise PFS or OS – ESMO Open

ESMO Open shared a post on X:

“Impact of treatment discontinuation among patients with MSI or MRD metastatic CRC treated with immune checkpoint inhibitors in ESMO Open. Early discontinuation of ICIs in patients without progression did not compromise PFS or OS”

Title: Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors

Authors: J. Ros, M.C. de Grandis, V. Navarro, I. Baraibar, F. Salva, C. Vaghi, A. Garcia, A. Alcaraz, A.M. López, M. Rodriguez, C. Salvà, N. Mulet-Margalef, J.L. Manzano, R. Querol, M. Pampols, E. Castillo, A. Vivancos, J. Tabernero, E. Elez

Read the Article

ESMO Open

Other articles about ESMO on OncoDaily.

A. Alcaraz A. Garcia A. Vivancos A.M. López C. Salvà C. Vaghi cancer E. Castillo E. Elez ESMO Open F. Salva I. Baraibar J. Ros J. Tabernero J.L. Manzano M. Pampols M. Rodriguez M.C. De Grandis N. Mulet-Margalef OncoDaily Oncology R. Querol V. Navarro